US sup­ports ex­ten­sion for Covid-19 IP waiv­er de­ci­sion

Af­ter much de­bate, the US gov­ern­ment is now call­ing for a dead­line ex­ten­sion to dis­cuss a con­tro­ver­sial po­ten­tial IP waiv­er for Covid-19 di­ag­nos­tics and ther­a­peu­tics.

Over the last five months, the Of­fice of the Unit­ed States Trade Rep­re­sen­ta­tive said it has con­sult­ed with mem­bers of Con­gress, pub­lic health ad­vo­cates, or­ga­nized la­bor groups, aca­d­e­mics, think tanks, com­pa­nies and trade as­so­ci­a­tions on the WTO’s re­cent TRIPS agree­ment, which es­tab­lished a 5-year waiv­er of cer­tain patent re­quire­ments on Covid-19 vac­cines.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.